BHV-7000 Epilepsy Enrollment Paused After FDA Partial Hold

Evidence Regulatory disclosure · Discovery September 10, 2026 · Importance 5/5 · Direction Negative Summary The FDA placed a partial clinical hold on Biohaven’s BHV-7000 epilepsy program after requesting more information about a specific metabolite observed in rodent testing. New enrollment is paused in the…